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Abstract
Background: Triglycerides (TG)/high-density lipoprotein (HDL) cholesterol ratio is a marker of small/dense low-density
lipoprotein particles, which are closely associated with various metabolic and vascular diseases. However, the role of
TG/HDL cholesterol ratio in cerebrovascular diseases has not been well studied. In this study, we evaluated the
relationship between TG/HDL cholesterol ratio and the presence of silent brain infarct (SBI) in a neurologically healthy
population.
Methods: We retrospectively evaluated consecutive participants in health check-ups between January 2006
and December 2013. SBI was defined as an asymptomatic, well-defined lesion with a diameter of ≥3 mm on
T1- or T2-weighted images. TG/HDL cholesterol ratio was calculated after dividing absolute TG levels by
absolute HDL cholesterol levels.
Results: Of 3172 healthy participants, 263 (8.3%) had SBI lesions. In multivariate analysis, TG/HDL cholesterol
ratio was independently associated with SBI (adjusted odds ratio [aOR] = 1.16, 95% confidence interval [CI] =
1.00 to 1.34, P = 0.047). This association was prominent in males (aOR = 1.23, 95% CI = 1.03 to 1.48, P = 0.021),
but not in females. In the analyses of the relationships between lipid parameters and SBI lesion burden, TG/
HDL cholesterol ratio was positively correlated, and total cholesterol/TG ratio was negatively correlated with
SBI lesion burden, in dose-response manners (P for trend = 0.015 and 0.002, respectively).
Conclusions: The TG/HDL cholesterol ratio was positively associated with the prevalence of SBI in a
neurologically healthy population.
Keywords: Triglycerides; High-density lipoprotein; Silent brain infarct; Lacune; Cerebral small vessel diseases;
Metabolic syndrome
Background
Silent brain infarct (SBI) is a subclinical pathology that is
commonly found prior to ischemic stroke, especially in the
elderly [1, 2]. Ischemic stroke often results in disabilities
with limited neurological recoveries [3]. Therefore, it is im-
portant to evaluate modifiable risk factors for SBI and es-
tablish an early intervention prior to ischemic stroke.
Several risk factors and possible pathophysiological mecha-
nisms for SBI have been suggested (e.g., lipohyalinosis,
atherosclerosis, and endothelial dysfunction), [4–6] how-
ever, there is still a lack of knowledge in this area.
For stroke clinicians, serum cholesterol level is a well-
known risk factor. International guidelines recommend
the control of lipid profiles, particularly low-density lipo-
protein (LDL) levels [7, 8]. Recently, investigators have
paid attention to the role of LDL particle phenotypes, ra-
ther than their total amounts, in the development of
vascular complications [9, 10]. Small/dense LDL parti-
cles have atherogenic roles, while larger ones seem to
have protective effects [11–14]. However, direct deter-
mination of the LDL phenotype is expensive and not yet
standardized [9, 10, 15]. Thus, application in clinical
practice is still premature.
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The size of LDL particles is inversely determined by cir-
culating triglyceride (TG) and very low-density lipoprotein
(VLDL) levels [9, 10]. Using this nature, investigators can
identify LDL phenotypes based on the ratio of TG and
high-density lipoprotein (HDL), which has been con-
firmed in direct validation studies [9–12, 15, 16]. Similar
to small/dense LDL particles, high TG/HDL cholesterol
ratio is also associated with insulin resistance (IR), meta-
bolic diseases, and cardio/cerebrovascular diseases [17–
21]. In this study, we evaluated the relationship between




We retrospectively evaluated 3257 participants from a
consecutive registry of routine health check-ups at the
Seoul National University Hospital Health Promotion
Center between January 2006 and December 2013. Brain
magnetic resonance imaging (MRI), magnetic resonance
angiography (MRA), and laboratory examinations were
conducted in all participants. Among them, 64 partici-
pants who had a history of stroke or severe neurological
deficit were excluded. Subjects with missing covariate
data (n = 18) and those under 30 years of age (n = 3)
were also excluded. Finally, a total of 3172 neurologically
healthy participants were analyzed (Fig. 1). The current
study was approved by the Institutional Review Board at
the Seoul National University Hospital (IRB number: H-
1502-026-647) and any data not published within the
article will be available from the corresponding author
upon reasonable request.
Clinical assessment
We evaluated demographic and metabolic factors, includ-
ing age, sex, body mass index, hypertension, diabetes,
hyperlipidemia, ischemic heart disease, current smoking,
current alcohol use, and use of antiplatelet, antihypertensive
or statin medication [22]. Laboratory examinations, in-
cluding glucose profiles, lipid profiles, high-sensitivity
C-reactive protein (hs-CRP) levels, and white blood cell
counts, were also conducted after 12 h of overnight
fasting [22].
Lipid profiles included those of total cholesterol (TC),
LDL cholesterol, HDL cholesterol, and TG. The TG/
HDL cholesterol ratio was calculated after dividing abso-
lute TG levels by absolute HDL cholesterol levels in per-
ipheral blood. Up to date, numerous novel indices have
been developed from the classic lipid profiles, and they
indicate additional information about LDL phenotype
and vascular risk factors [8, 17, 21]. Thus, in addition to
TG/HDL ratio, we also calculated TC/TG ratio which
positively determines LDL particle size [8, 13].
Radiological assessment
All participants underwent brain MRI and MRA using a
1.5-Tesla MR scanner (Magnetom SONATA, Siemens,
Munich, Germany or Signa, GE Healthcare, Milwaukee,
WI, USA). The basic thickness of brain MRI was 5 mm,
and detailed acquisition parameters were as follows: T1-
weighted images (repetition time [TR]/echo time [TE] =
500/11 ms); T2 fluid-attenuated inversion recovery im-
ages (TR/TE = 8800/127 ms); T2-weighted images (TR/
TE = 5000/127 ms); T2-gradient echo images (TR/TE =
57/20 ms); and three-dimensional time-of-flight MRA
images (TR/TE = 24/3.5 ms, slice thickness = 1.2 mm).
SBI was defined as an asymptomatic, well-defined le-
sion of ≥3 mm with the same signal characteristics as
cerebrospinal fluid on T1- or T2-weighted images [1].
The burden of SBI lesions was classified as absent, sin-
gle, or multiple. Intracranial atherosclerosis (ICAS) was
defined as an occlusion or stenosis greater than 50% of
an intracranial vessel on MRA [23]. All radiological
markers were rated by two neurologists (K.-W.N. and
H.-Y.J.). Disagreements were resolved by discussion with
a third rater (H.-M.K.).
Statistical analysis
All statistical analyses were performed using SPSS version
23 (IBM SPSS, Chicago, IL, USA). To compare the base-
line characteristics between participants with SBI and
those without SBI, Student’s t-test or the Mann-Whitney
U-test were used for continuous variables, and the chi-
squared test or Fisher’s exact test were used for categorical
variables. Variables with P < 0.05 in the univariate analysis
and sex, LDL cholesterol were introduced as confounders
in the multivariate logistic regression analysis. To elimin-
ate the effect of lipid-lowering agents, we conducted add-
itional sensitivity analysis after excluding 233 participants
who were taking statin. Lipid profiles, especially TG and
HDL cholesterol levels, are highly influenced by sex [19,
Fig. 1 Patients inclusion flow-chart
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24]. Therefore, we also conducted additional subgroup
analyses in both male and female groups. Furthermore, to
understand underlying pathophysiology, we compared
various lipid parameter according to SBI lesion burden
using the Kruskal-Wallis test, and the Jonckheere-
Terpstra test. In this study, statistical significance was con-
sidered at P < 0.05.
Results
A total of 3172 healthy subjects were assessed (median age:
56 years; male sex: 54.0%). SBI lesions were found in 263
(8.3%) participants, and the median TG/HDL cholesterol
ratio was 1.87 [1.23–3.02]. The baseline characteristics of
the cohort are presented in Table 1. In univariate analyses,
SBI (+) group was associated with age, hypertension, dia-
betes, antiplatelet medication, ICAS, and levels of fasting
glucose, TC, LDL cholesterol, HDL cholesterol, TG, non-
HDL cholesterol, TG/HDL cholesterol ratio, TC/TG ratio,
and hs-CRP (Table 2).
In multivariate analysis to evaluate the possible predic-
tors of SBI, TG/HDL cholesterol ratio (adjusted odds
ratio [aOR] = 1.16, 95% confidence interval [CI] = 1.00 to
1.34, P = 0.047) remained a significant predictor of SBI,
after adjustment for confounders (Table 3). Age and
hypertension were also associated with SBI, independ-
ently of TG/HDL cholesterol ratio. Furthermore, this as-
sociation was more prominent in males (aOR = 1.23,
95% CI = 1.03 to 1.48, P = 0.021), but not in females.
When we conducted additional sensitivity analysis to ex-
clude the effect of statins, the close association between
TG/HDL cholesterol ratio and SBI was confirmed (Add-
itional file 1).
In the analyses of the relationships between lipid param-
eters and SBI lesion burden, TG/HDL cholesterol ratio
was positively correlated (P = 0.046) and TC/TG ratio was
negatively correlated (P = 0.007) with SBI lesion burden,
even in dose-response manners (P for trend = 0.015 and
0.002, respectively) (Fig. 2). There was no significant cor-
relation between TG (P = 0.113) or HDL cholesterol (P =
0.059) and SBI lesion burden; however, they presented
tendencies for dose-response relationships (P for trend =
0.037 and 0.026, respectively).





Age, y [IQR] 56 [50–63] 56 [50–63] 57 [51–63]
Sex, male, n (%) 1713 (54.0) N/A N/A
Body mass index, kg/m2 [IQR] 24.03 [22.11–25.96] 24.48 [22.73–26.35] 23.47 [21.53–25.43]
Hypertension, n (%) 712 (22.4) 420 (24.5) 292 (20.0)
Diabetes, n (%) 437 (13.8) 390 (16.9) 147 (10.1)
Hyperlipidemia, n (%) 808 (25.5) 403 (23.5) 405 (27.8)
Ischemic heart disease, n (%) 124 (3.9) 73 (4.3) 51 (3.5)
Current smoking, n (%) 489 (15.4) 445 (26.0) 44 (3.0)
Current alcohol use, n (%) 1539 (48.5) 1148 (67.0) 391 (26.8)
On antiplatelet medication, n (%) 326 (10.3) 210 (12.3) 116 (8.0)
On antihypertensive, n (%) 699 (22.0) 371 (21.7) 328 (22.5)
On statin, n (%) 256 (8.1) 143 (8.3) 113 (7.7)
Fasting glucose, mg/dL [IQR] 91 [85–101] 93 [86–104] 90 [84–99]
Total cholesterol, mg/dL [IQR] 198 [174–223] 194 [172–219] 202 [178–227]
LDL cholesterol, mg/dL [IQR] 124 [101–147] 123 [101–147] 126 [102–148]
HDL cholesterol, mg/dL [IQR] 53 [45–63] 49 [42–58] 57 [49–67]
Triglycerides, mg/dL [IQR] 100 [73–144] 110 [78–159] 91 [69–125]
TG/HDL cholesterol ratio [IQR] 1.87 [1.23–3.02] 2.21 [1.43–3.56] 1.56 [1.09–2.42]
TC/TG ratio [IQR] 1.95 [1.36–2.67] 1.74 [1.23–2.44] 2.21 [1.60–2.94]
White blood cells, × 103/μL [IQR] 5.31 [4.40–6.37] 5.61 [4.66–6.82] 5.03 [4.15–5.98]
hs-CRP, mg/dL [IQR] 0.04 [0.01–0.15] 0.06 [0.01–0.16] 0.03 [0.01–0.13]
Silent brain infarct, n (%) 263 (8.3) 146 (8.5) 117 (8.0)
Intracranial atherosclerosis, n (%) 95 (3.0) 51 (3.0) 44 (3.0)
LDL low-density lipoprotein, HDL high-density lipoprotein, TG triglyceride, TC total cholesterol, hs-CRP high-sensitivity C-reactive protein
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Discussion
In this study, we demonstrated that TG/HDL cholesterol ra-
tio was positively associated with the prevalence of SBI in a
neurologically healthy population. Since this association also
occurred in a dose-response manner, our findings may sug-
gest clues for the underlying pathophysiologic mechanisms.
Obviously, our main findings revealed that a pattern
of “high-TG and low-HDL cholesterol” pattern may be
harmful. This “atherogenic dyslipidemia” has been re-
cently focused, because it is considered as a surrogate
marker of small/dense LDL particles and IR status [11,
19, 25, 26]. Our results could be interpreted in two
ways: first, as we mentioned, high TG/HDL cholesterol
ratio indicates harmful small/dense LDL particles that
could contribute to cerebrovascular diseases [12–14,
25]. Another index (i.e., TC/TG ratio), which positively
reflects LDL particle size, [13] also confirmed this idea.
Second, the hypertriglyceridemia itself could have
harmful effects on cerebrovascular diseases, which is in
line with previous studies [27, 28]. Regardless of the in-
terpretation, high TG levels, which are treated with a
little different medication from that for high TC or LDL
levels, should be controlled.
The exact mechanisms underlying the relationship be-
tween TG/HDL cholesterol ratio and SBI are unclear.
However, we suggest several plausible explanations: first,
high TG/HDL cholesterol ratio may indicate higher ath-
erosclerosis burden. TG/HDL cholesterol ratio is closely
associated with atherosclerosis regardless of their stenosis
degree [8, 17, 29, 30]. It can result from small/dense LDL
particles which are susceptible to oxidation, leading to
atherogenesis [12, 26]. VLDL, which coexists with athero-
genic dyslipidemia, also accelerates atherosclerosis by be-
ing taken into macrophages and developing foam cells
[26]. Because advanced atherosclerosis can result in
diffuse-hypoperfusion, extravasation of toxic metabolites
into neural tissues, and occlusion of small arterioles, [22]
high TG/HDL cholesterol may ratio be associated with the
prevalence of SBI through higher atherosclerosis burden;
second, inflammation and oxidative stress may play a role.
TG/HDL cholesterol ratio indicates IR status, [17, 18, 29,
31, 32] and then, it also means increased subclinical in-
flammation, disturbed metabolic status, and elevated sym-
pathetic tone [31, 33]. This high inflammation burden
promote downstream of lipid peroxidation and cellular/
DNA damage, leading to endothelial dysfunction/arterial






Age, y [IQR] 56 [50–62] 63 [57–69] < 0.001
Sex, male, n (%) 1567 (53.9) 146 (55.5) 0.608
Body mass index, kg/m2 [IQR] 24.00 [22.12–25.95] 24.24 [22.05–26.18] 0.357
Hypertension, n (%) 619 (21.3) 93 (35.4) < 0.001
Diabetes, n (%) 378 (13.0) 59 (22.4) < 0.001
Hyperlipidemia, n (%) 737 (25.4) 71 (27.0) 0.562
Ischemic heart disease, n (%) 110 (3.8) 14 (5.3) 0.217
Current smoking, n (%) 455 (15.6) 34 (12.9) 0.243
Current alcohol use, n (%) 1419 (48.8) 120 (45.6) 0.327
On antiplatelet medication, n (%) 285 (9.8) 41 (15.6) 0.003
On antihypertensive, n (%) 635 (21.8) 64 (24.3) 0.348
On statin, n (%) 233 (8.0) 23 (8.7) 0.675
Fasting glucose, mg/dL [IQR] 91 [85–101] 94 [85–109] 0.003
Total cholesterol, mg/dL [IQR] 198 [175–223] 191 [166–218] 0.003
LDL cholesterol, mg/dL [IQR] 125 [102–147] 117 [90–147] 0.009
HDL cholesterol, mg/dL [IQR] 53 [45–63] 51 [43–61] 0.028
Triglycerides, mg/dL [IQR] 99 [72–144] 107 [77–148] 0.037
TG/HDL cholesterol ratio [IQR] 1.85 [1.22–2.98] 2.12 [1.31–3.38] 0.016
TC/TG ratio [IQR] 1.97 [1.39–2.69] 1.74 [1.20–2.49] 0.002
White blood cells, × 103/μL [IQR] 5.30 [4.40–6.36] 5.48 [4.44–6.77] 0.054
hs-CRP, mg/dL [IQR] 0.04 [0.01–0.15] 0.07 [0.01–0.17] 0.039
Intracranial atherosclerosis, n (%) 80 (2.8) 15 (5.7) 0.007
LDL low-density lipoprotein, HDL high-density lipoprotein, TG triglyceride, TC total cholesterol, hs-CRP high-sensitivity C-reactive protein
Nam et al. BMC Neurology          (2019) 19:147 Page 4 of 8
stiffness. Supporting these ideas, several studies have re-
ported a direct relationship between TG/HDL cholesterol
ratio and arterial stiffness. We also found that subjects
with higher TG/HDL cholesterol ratio had higher levels of
inflammatory markers (e.g., hs-CRP and white blood cell
counts) (Table 4) [14, 17]. Because endothelial dysfunc-
tion/arterial stiffness is one of leading causes of SBI devel-
opment, [5] subclinical inflammation and endothelial
dysfunction may provide a connection between TG/HDL
cholesterol ratio and SBI prevalence; lastly, TG/HDL chol-
esterol ratio could be a simple surrogate marker of sub-
jects who have numerous vascular risk factors. We already
knew that TG/HDL cholesterol ratio is related to various
metabolic risk factors that are also risk factors for SBI
[17–19]. Thus, subjects with higher TG/HDL cholesterol
ratio may have additional vascular risk factors that con-
tribute to SBI (Table 4).
Interestingly, our results were more prominent in male
participants. The exact reason for this sexual difference
is unclear. However, we suggest several possible explana-
tions: first, males had higher TG and lower HDL choles-
terol values than those of females. Thus, the ratio of
participants who had abnormal TG/HDL cholesterol ra-
tio to normal ones may be prominent in males, and
males had larger effect size. This could make more
prominent association between TG/HDL cholesterol ra-
tio and SBI. second, as we shown in Table 1, male partic-
ipants had more frequent vascular risk factors than
females, except for older age, and all of these metabolic
and inflammatory factors were also closely related to
Table 3 Multivariate analysis of possible predictors of silent brain infarct
Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
Total
Agea 2.28 (1.98 to 2.63) < 0.001 1.10 (1.09 to 1.12) < 0.001
Sex 1.07 (0.83 to 1.38) 0.608 1.02 (0.75 to 1.39) 0.890
Hypertension 2.02 (1.55 to 2.65) < 0.001 1.17 (0.83 to 1.65) 0.037
Diabetes 1.94 (1.42 to 2.64) < 0.001 1.31 (0.90 to 1.89) 0.157
On antiplatelet medication 1.70 (1.19 to 2.43) 0.003 1.20 (0.80 to 1.79) 0.372
hs-CRPa 1.12 (1.03 to 1.21) 0.008 1.07 (0.96 to 1.18) 0.219
ICAS 2.14 (1.21 to 3.77) 0.009 0.94 (0.44 to 2.00) 0.865
LDL cholesterola 0.83 (0.71 to 0.96) 0.012 0.96 (0.83 to 1.13) 0.637
TG/HDL cholesterol ratioa 1.13 (1.01 to 1.26) 0.030 1.16 (1.00 to 1.34) 0.047
Male
Agea 2.44 (2.02 to 2.94) < 0.001 1.11 (1.08 to 1.14) < 0.001
Hypertension 2.27 (1.60 to 3.22) < 0.001 1.44 (0.92 to 2.24) 0.111
Diabetes 1.69 (1.13 to 2.52) 0.010 1.14 (0.71 to 1.85) 0.587
On antiplatelet medication 1.99 (1.30 to 3.07) 0.002 1.31 (0.79 to 2.16) 0.294
hs-CRPa 1.17 (1.06 to 1.29) 0.002 1.08 (0.96 to 1.22) 0.206
ICAS 2.06 (0.95 to 4.46) 0.068 1.28 (0.49 to 3.32) 0.617
LDL cholesterola 0.74 (0.60 to 0.90) 0.003 0.94 (0.76 to 1.17) 0.590
TG/HDL cholesterol ratioa 1.08 (0.94 to 1.24) 0.289 1.23 (1.03 to 1.48) 0.021
Female
Agea 2.09 (1.69 to 2.59) < 0.001 1.09 (1.06 to 1.12) < 0.001
Hypertension 1.72 (1.13 to 2.62) 0.012 0.88 (0.51 to 1.54) 0.656
Diabetes 2.40 (1.47 to 3.93) < 0.001 1.72 (0.95 to 3.11) 0.073
On antiplatelet medication 1.22 (0.64 to 2.35) 0.546 0.92 (0.45 to 1.86) 0.811
hs-CRPa 1.01 (0.84 to 1.23) 0.898 1.02 (0.82 to 1.27) 0.848
ICAS 2.24 (0.98 to 5.15) 0.057 0.67 (0.19 to 2.39) 0.532
LDL cholesterola 0.95 (0.76 to 1.19) 0.657 1.00 (0.80 to 1.26) 0.989
TG/HDL cholesterol ratioa 1.26 (1.03 to 1.53) 0.023 1.06 (0.82 to 1.36) 0.672
hs-CRP high-sensitivity C-reactive protein, ICAS intracranial atherosclerosis, TG triglyceride, HDL high-density lipoprotein
aThese variables were standardized by division by the standard deviation
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Fig. 2 The association between lipid parameters and SBI lesion burden. a TG/HDL cholesterol ratio correlated positively and b TC/TG ratio
correlated negatively with SBI lesion burden, in dose-response manners (P for trend = 0.015 and 0.002, respectively). c TG and d HDL cholesterol
also showed tendencies toward correlations with SBI lesion burden in dose-response manners, yet not significantly so








Number 1057 1056 1059
Age, y [IQR] 55 [50–63] 57 [52–63] 56 [49–63] 0.386
Sex, male, n (%) 421 (39.7) 555 (52.7) 737 (69.7) < 0.001
Body mass index, kg/m2 [IQR] 22.92 [21.11–24.80] 24.14 [22.26–26.00] 24.98 [23.37–26.93] < 0.001
Hypertension, n (%) 184 (17.3) 255 (24.2) 273 (25.8) < 0.001
Diabetes, n (%) 99 (9.3) 143 (13.6) 195 (18.4) < 0.001
Ischemic heart disease, n (%) 40 (3.8) 36 (3.4) 48 (4.5) 0.361
Current smoking, n (%) 86 (8.1) 124 (11.8) 279 (26.4) < 0.001
Current alcohol use, n (%) 467 (44.0) 505 (47.9) 567 (53.6) < 0.001
Fasting glucose, mg/dL [IQR] 89 [82–97] 92 [85–101] 95 [87–105] < 0.001
White blood cells, × 103/μL [IQR] 4.81 [4.00–5.83] 5.28 [4.42–6.21] 5.90 [4.92–7.12] < 0.001
hs-CRP, mg/dL [IQR] 0.02 [0.01–0.11] 0.05 [0.01–0.15] 0.09 [0.01–0.18] < 0.001
hs-CRP high-sensitivity C-reactive protein
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TG/HDL cholesterol ratio (Table 4). TG/HDL choles-
terol ratio in male group might more clearly reflect vul-
nerable conditions underlying SBI development than
female group. Last, another explanation is based on the
distribution of the adipose tissue according to sex. Males
have higher proportions of visceral adipose tissues,
which are the sources of circulating TG, while females
have a lot of subcutaneous adipose tissues with metabol-
ically protective effects [34]. These biological discrepan-
cies may explain the difference in TG/HDL cholesterol
ratio, and its effect on SBI development.
Our study has several considerable limitations. First, it
was designed as a retrospective, single-center study. We
included a relatively large number of participants, and
broadly evaluated their lipid profiles and brain MRI data.
However, the possibility of selection bias still exists. Sec-
ond, due to the nature of the cross-sectional analyses,
we could not establish a causal relationship between
TG/HDL cholesterol ratio and SBI. Further prospective
randomized controlled studies are needed to identify
causal relationships and underlying patho-mechanisms.
Third, we could not directly measure small/dense LDL
particle levels. If we included directly measured small/
dense LDL particle levels, we could investigate whether
TG/HDL cholesterol ratio is only a surrogate marker for
small/dense LDL particles or it also plays an individual
role in SBI development. Fourth, although we have con-
sidered the effects of statin on our outcomes, other
lipid-lowering agents such as fenofibrate may also influ-
ence the relationship between SBI and TG/HDL ratio.
Last, SBI can not only be from atherosclerotic vascular
diseases. Bias from other possible pathologies (e.g., vas-
culitis, dissection, cardioembolic sources, hypercoagula-
bility) should be considered.
Conclusion
A high TG/HDL cholesterol ratio may be a risk factor for
the prevalence and burden of SBI lesions in a neurologically
healthy population. Because SBI is a risk factor for subse-
quent ischemic stroke, [2] our simple, inexpensive, but effi-
cient method could identify modifiable high-risk group
which requires early intervention. However, our findings
should be confirmed with further prospective studies.
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